Literature DB >> 33961690

Progressive and Parallel Decline of Humoral and T-Cell Immunity in Convalescent Healthcare Workers with Asymptomatic or Mild-to-Moderate Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Jose L Casado1, Pilar Vizcarra1, Hector Velasco2, Johannes Hammerle3, Amaranta McGee4, Marina Fernandez-Escribano3, Alejandro Vallejo1,2.   

Abstract

We investigated the duration of humoral and T-cell immune response in paired samples among 22 convalescent healthcare workers (HCWs). A median of 1.8 months after diagnosis, T-cell response was significantly lower in HCWs with early loss of antibodies (6 cases [27%]). After 5.1 months, antibody decline was observed in 77% of cases (41% seroreverted; P < .01), and 36% had lost T-cell response (75% lost response to spike protein). Persistence of immune response was observed in those who developed a greater adaptive immune response. Our data point to the initial immune response as the relevant player in coronavirus disease 2019 duration of protection.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  SARS-CoV-2; adaptive immune response; convalescent; duration; healthcare workers; immune response

Year:  2021        PMID: 33961690      PMCID: PMC8136002          DOI: 10.1093/infdis/jiab242

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity.

Authors:  Jose L Casado; Johannes Haemmerle; Pilar Vizcarra; Mario Rodriguez-Dominguez; Tamara Velasco; Hector Velasco; Elena Centenera; Beatriz Romero-Hernandez; Marina Fernandez-Escribano; Alejandro Vallejo
Journal:  Clin Transl Immunology       Date:  2021-09-08

2.  SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.

Authors:  Willem A Mak; Johannes G M Koeleman; Marijke van der Vliet; Frans Keuren; David S Y Ong
Journal:  J Infect       Date:  2021-12-09       Impact factor: 6.072

3.  BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.

Authors:  Pilar Vizcarra; Johannes Haemmerle; Hector Velasco; Tamara Velasco; Marina Fernández-Escribano; Alejandro Vallejo; José L Casado
Journal:  Vaccine       Date:  2021-11-11       Impact factor: 4.169

4.  The effect of age on the magnitude and longevity of Th1-directed CD4 T-cell responses to SARS-CoV-2.

Authors:  Ryan G Nattrass; Lisa Krafft; Polina Zjablovskaja; Marc Schuster; Bahram Kasmapour; Cem Sarisoy; Jessica Minich; Elena Bach; Hendrik Streeck
Journal:  Immunology       Date:  2022-04-22       Impact factor: 7.215

5.  Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination.

Authors:  José L Casado; Johannes Haemmerle; Pilar Vizcarra; Gema Ramirez-Alonso; Andrea Salazar-Tosco; Beatriz Romero-Hernandez; Magdalena Blasco; Mario Rodriguez-Dominguez; Itria G Mirabella; Alejandro Vallejo; Marina Fernandez-Escribano
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

6.  Impact of SARS-CoV-2-specific memory B cells on the immune response after mRNA-based Comirnaty vaccine in seronegative health care workers.

Authors:  Alejandro Vallejo; Pilar Vizcarra; Adrián Martín-Hondarza; Sandra Gómez-Maldonado; Johannes Haemmerle; Héctor Velasco; José L Casado
Journal:  Front Microbiol       Date:  2022-09-23       Impact factor: 6.064

7.  Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel.

Authors:  Vivian Glück; Sonja Grobecker; Josef Köstler; Leonid Tydykov; Manuela Bertok; Tanja Weidlich; Christine Gottwald; Bernd Salzberger; Ralf Wagner; Florian Zeman; Michael Koller; André Gessner; Barbara Schmidt; Thomas Glück; David Peterhoff
Journal:  Infection       Date:  2021-09-25       Impact factor: 3.553

8.  Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination.

Authors:  Ellie Taus; Christian Hofmann; Francisco Javier Ibarrondo; Mary Ann Hausner; Jennifer A Fulcher; Paul Krogstad; Kathie G Ferbas; Nicole H Tobin; Anne W Rimoin; Grace M Aldrovandi; Otto O Yang
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.